港股异动 | 复宏汉霖(02696)再涨超8% 广谱抗肿瘤PD-L1 ADC HLX43末线食管鳞癌II期数据首次发布

智通财经
Jan 13

智通财经APP获悉,复宏汉霖(02696)再涨超8%,截至发稿,涨8.05%,报69.8港元,成交额1864.08万港元。

消息面上,1月9日,复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)上,首度公布了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌(ESCC)的II期概念验证(POC)数据,本次发布的数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力,展现出令人鼓舞的疗效及良好的安全性。HLX43已在非小细胞肺癌、宫颈癌、食管鳞癌及胸腺癌等多项实体瘤适应症中观察到持续且一致的疗效和安全性趋势,其广谱抗肿瘤潜力正通过临床实践逐步得到验证,为后续拓展更多适应症奠定重要基础。

值得注意的是,第44届摩根大通医疗健康年会(JPM 2026)将于1月12–15日在美国旧金山举行。作为全球医疗健康领域最具影响力的年度盛会之一,JPM大会被视为全球资本市场观察医药创新与产业趋势的重要窗口。复宏汉霖执行董事兼首席执行官朱俊博士将于当地时间1月15日在大会上发表主题演讲,围绕公司全球化2.0阶段的发展路径、创新管线布局及中长期战略规划,向国际投资人与产业界系统分享复宏汉霖的最新进展与未来蓝图。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10